Shareholder Class Action

In a federal class action, shareholders say directors are selling Abaxis (medical devices) too cheaply through an unfair process to Zoetis, for $83 a share or $2 billion.

SAN FRANCISCO (CN) — In a federal class action, shareholders say directors are selling the medical-device company Abaxis too cheaply through an unfair process to Zoetis, for $83 a share or $2 billion.

Categories / Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Shareholder Class Action

Subscribe to Closing Arguments

Additional Reads